Paradigm Biocapital Advisors LP: ORUKA THERAPEUTICS INC (ORKA): Quarterly 13F Position History
As of Q2 2026, Paradigm Biocapital Advisors LP reported 2,144,526 shares of ORUKA THERAPEUTICS INC (ORKA), worth $204.1M and representing 3.8% of its 13F equity book. Quarter-over-quarter share count change: 175,790 (-7.6%) . The position first appeared in Q3 2024 and has been disclosed across 8 13F-HR filings in Pactolio's tracked window.
- 2,144,526Shares Held (Latest Filing)
- $204.1MReported Market Value (Latest Filing)
- 3.8%Portfolio Weight (% of 13F Equity Book)
- 175,790Quarter-over-Quarter Share Change
- +$90.3MQuarter-over-Quarter Value Change
- 2,320,316Peak Reported Shares (Historical)
Quarterly 13F-HR Disclosure History Source: SEC 13F-HR filings, 8 quarter s
| Quarter | Shares | QoQ Share Change | Share Change (%) | Market Value | Weight | Implied Price |
|---|---|---|---|---|---|---|
| Q2 2026 | 2,144,526 | 175,790 | -7.6% | $204.1M | 3.8% | $95.2 |
| Q1 2026 | 2,320,316 | +610,000 | +35.7% | $113.8M | 2.3% | $49.0 |
| Q4 2025 | 1,710,316 | +1,710,316 | – | $51.8M | 1.4% | $30.3 |
| Q3 2025 | 0 | 0 | – | $0 | 0.0% | – |
| Q2 2025 | 0 | 0 | – | $0 | 0.0% | – |
| Q1 2025 | 0 | 819,660 | -100.0% | $0 | 0.0% | – |
| Q4 2024 | 819,660 | +100,000 | +13.9% | $15.9M | 0.6% | $19.4 |
| Q3 2024 | 719,660 | – | – | $17.6M | 0.6% | $24.5 |
Methodology & FAQ
How This Position History Is Sourced
Each row is one SEC Form 13F-HR filing disclosing this position. Share count, market value, and reported quarter are taken verbatim from the filing; portfolio weight is recomputed against the same filing's total reported equity book. Implied price-per-share is market value divided by shares, a quarter-end mark rather than the manager's cost basis. See the full methodology document for the normalization rules.
When did Paradigm Biocapital Advisors LP first disclose a ORKA position in 13F-HR filings?
Paradigm Biocapital Advisors LP first reported ORUKA THERAPEUTICS INC (ORKA) on its 13F-HR filing for the period ending 2024-09-30 (Q3 2024). The position has appeared on 8 reported quarters within Pactolio's tracked window.
What was Paradigm Biocapital Advisors LP's most recent quarter-over-quarter share-count change in ORKA?
Between Q1 2026 and Q2 2026, Paradigm Biocapital Advisors LP reduced its ORKA position by 175,790 shares (-7.6%), leaving 2,144,526 shares at a market value of $204.1M.
Does the implied price-per-share represent Paradigm Biocapital Advisors LP's cost basis in ORKA?
No. The implied price-per-share column is the 13F-HR reported market value divided by reported share count on the filing date (end of quarter). It is a quarter-end mark, not a cost basis or transaction price. Use it as a sanity check on the value column, not as an indicator of the manager's entry or exit price.